Department of Vascular Surgery, University Hospital, LMU Munich, Germany.
Department of Vascular Surgery, University Hospital, LMU Munich, Germany; Department of Cardiothoracic and Vascular Surgery, Evangelismos General Hospital of Athens, Athens, Greece.
Eur J Vasc Endovasc Surg. 2022 May;63(5):759-767. doi: 10.1016/j.ejvs.2022.02.027. Epub 2022 Feb 25.
To synthesise and present all available evidence regarding the surgical treatment of patients with aberrant subclavian artery (aSA) pathologies during the last 30 years. The study also aimed to create a checklist of suggested reporting items to help increase reporting homogeneity.
A systematic search of medical databases was performed to identify all studies published between 1990 and 2020 reporting on the outcomes of patients undergoing surgery for an aSA pathology. Patients were divided into two groups; Group A included patients undergoing open or hybrid surgery through sternotomy/thoracotomy and Group B included patients undergoing endovascular or hybrid treatment without chest access. The % crude rates (CR) of all variables of interest were calculated. A proportion meta-analysis was performed reporting pooled rates with 95% confidence intervals (CIs).
Three hundred and fourteen studies were identified reporting on the surgical outcomes of 732 patients (60.1% males; 440/732). The quality of evidence was generally low, with 286 studies including fewer than four patients and 28 studies with five or more cases. Aberrant right subclavian artery (aRSA) in a left sided aortic arch was present in 71.4% of the patients and a Kommerell's diverticulum was present in 50.1% of the cases. A total of 68% of the patients were symptomatic on presentation, with the majority complaining of dysphagia (49.6%). Group A included 453 and Group B 279 patients. Studies reporting on five or more patients were included in the main meta-analysis. The pooled early mortality rate was 1.62% (95% CI 0.05% - 4.53%) in Group A and 1.96% (95% CI 0 - 6.34%) in Group B. Pooled rates of symptom relief were 99.52% (95% CI 92.05% - 100.00%) in Group A and 95.79% (95% CI 83.96% - 100.00%) in Group B.
The surgical techniques used to treat aSA and aortic pathologies involving an aSA had remarkably low mortality rates and high clinical success, regardless of the technique used.
综合并呈现过去 30 年来有关异常锁骨下动脉(aSA)病变患者外科治疗的所有可用证据。本研究还旨在制定一份报告建议项目清单,以帮助提高报告的同质性。
系统检索医学数据库,以确定 1990 年至 2020 年期间发表的所有报告 aSA 病变患者手术治疗结果的研究。患者分为两组;A 组包括通过胸骨切开术/开胸术进行开放或杂交手术的患者,B 组包括接受血管内或杂交治疗而无需胸部进入的患者。计算所有感兴趣变量的粗率(CR)。进行比例荟萃分析,报告合并率及其 95%置信区间(CI)。
确定了 314 项研究,报道了 732 例患者(60.1%为男性;440/732)的手术结果。证据质量普遍较低,286 项研究纳入的患者少于 4 例,28 项研究纳入的患者超过 5 例。71.4%的患者存在左侧主动脉弓的异常右锁骨下动脉(aRSA),50.1%的病例存在 Kommerell 憩室。68%的患者就诊时存在症状,大多数患者主诉吞咽困难(49.6%)。A 组包括 453 例患者,B 组包括 279 例患者。纳入了报告 5 例或更多患者的研究进行主要荟萃分析。A 组的早期死亡率为 1.62%(95%CI 0.05% - 4.53%),B 组为 1.96%(95%CI 0 - 6.34%)。A 组的症状缓解率为 99.52%(95%CI 92.05% - 100.00%),B 组为 95.79%(95%CI 83.96% - 100.00%)。
无论使用何种技术,用于治疗 aSA 和涉及 aSA 的主动脉病变的外科技术死亡率都很低,临床成功率很高。